Bruker Corp. (NSDQ:BRKR) subsidiary Bruker Daltonics Inc. signed a co-development and co-marketing deal with Franklin Lakes, N.J.-based Becton, Dickinson & Co. (NYSE:BDX) BD Diagnostics division.
Former Bruker Corp. (NSDQ:BRKR) executive Dirk Laukien and his half-brother Joerg Laukien — both directors at the Billerica, Mass.-based scientific instruments maker — late last week cashed in on another portion of their still-sizable stakes, each selling just under 540,000 shares of Bruker stock.
The Sept. 10 transactions went out at $13.27 a share, producing a combined $14.3 million in gross proceeds for the siblings.
Bruker Corp. (NSDQ:BRKR) registered for an initial public offering for its energy and superconducting subsidiary, Bruker Energy & Supercon Technologies Inc
The Billerica, Mass.-based laboratory equipment maker said it hasn’t determined how many shares it will offer or their price, but said it intends to "retain a controlling equity interest in BEST for the foreseeable future," according to a press release.
Bruker Corp. (NSDQ:BRKR) agreed to pay $229 million for Veeco Instruments Inc.’s (NSDQ:VECO) metrology business.
Plainville, N.Y.-based Veeco said its metrology business, which makes atomic force microscopes and optical measuring equipment, will be rolled into Billerica, Mass.-based Bruker’s nano instruments business.
Bruker Corp. (NSDQ:BRKR) elected Charles Wagner to its board of directors and audit committee.
The former Millipore (NYSE:MIL) CFO was also elected to the board of Bruker subsidiary Bruker Energy & Supercon Technologies Inc.
Wagner left his former post when Merck KGaA (NYSE:MRK) closed its $6 billion deal to acquire Billerica, Mass.-based Millipore.
Bruker Corp. (NSDQ:BRKR) saw a 19 percent jump in net earnings during the second quarter.
The Billerica, Mass.-based company reported net earnings of $23 million, or 14 cents per diluted share, on revenue of $301 million during the three months ended June 30. That compares with net earnings of $13 million, or 8 cents per diluted share, on sales of $253 million during the same period last year.
Bruker Corp. (NSDQ:BRKR) closed its $37.5 million acquisition of three former Varian Inc. product lines from Agilent Technologies Inc.(NYSE:A).
In March, the companies announced the deal to sell Billerica, Mass.-based Bruker the three Varian divisions so Agilent could comply with European anti-trust laws.
Boosted by a 20.6 percent jump in overall revenues — including $10 million in additional federal stimulus spending — scientific instruments maker Bruker Corp. (NSDQ:BRKR) cruised to a $16.1 million profit during the first three months of 2010.
The 10 cent-per-share first-quarter gain doubled reported earnings per share in the year-ago period and topped consensus analyst estimates for the quarter by 2 cents.
Bruker Daltonics expanded an existing marketing agreement with Dutch laboratory instruments maker Kiestra Lab Automation.
Financial details of the agreement were not announced, but the pact includes a joint research and development program for the companies to work on technologies together to sell to microbiology laboratories clients. The companies have already been working with customers in research facilities in The Netherlands.
Bruker Corp. (NSDQ:BRKR) director Collin D’Silva resigned his seat to take the helm of a new chemical analysis business based in California.
Earlier this week the Billerica, Mass.-based scientific instruments maker announced that D’Silva would cede his seat on its board of director’s audit committee. As it turns out, that was just the prelude to D’Silva stepping down from the board entirely to become division president of the Fremont, Calif.-based chemical analysis division of Bruker Daltonics.
The audit committee for Bruker Corp. (NYSE:BRKR) will have to do without the services of Collin D’Silva, who stepped down from the panel March 9 but remains a member of Bruker’s board of directors.
The Billerica, Mass.-based scientific instruments maker has 180 days from D’Silva’s resignation, or until Sept. 7, to find someone to replace him on the audit committee or it will risk de-listing from the NASDAQ stock exchange, according to a regulatory filing.